Since their introduction in the early 196Os, the oral contraceptive (OCs) steroids have been subjected to preclinical and clinical investigations unprecedented in medical history. As a result of such extensive studies, it is now possible to make a comprehensive review of preclinical and clinical data on,oral contraceptives. The OCs were introduced at a time when the Food and Drug Administration (FDA) was undergoing drastic changes as a result of the thalidomide tragedy, the introduction of the Kefauver-Harris Amendment, and, the desire for greater control over the pharmaceutical industry. The initial requirements for the safety evaluation of OCs were identical to those of other drugs. There were no explicit requirements for OCs although it was generally felt that the requirements should be more stringent because the OCs were being used in otherwise healthy women for long periods of time and with minimal medical supervision. In the 1960s when it became apparent from ongoing studies that there was an increased incidence of mammary tumors in dogs treated with some progestins, the FDA made the decision to terminate clinical studies and established the requircment for 7and 10-yr studies in dogs and monkeys, respectively. The primary purpose of this paper is to present an historical perspective of the evolution of the preclinical requiremcnts for the evaluation of the safety of OCs prior to their use in the various phases (I, 11, 111) of clinical trials. Some . proposed changes in the requirements are discussed. This information will form the basis for other presentations dealing with the safety assessment of OCs in rats, dogs, and monkeys.
INTRODUCTION
One of the most profound social and scientific changes affecting the life of women in the past 50 yrs was the emergence of oral contraceptives based primarily on the combination products containing estrogens and progestins. The technology has led to j. what was appropriately referred to as the "contraceptive revolution."
Oral contraceptives are probably the most widely studied drugs, and understandably so, because they are used by millions of healthy women during a major part of their reproductive life with minimal medical supervision. Safety, therefore, must be assured since the risk of adverse effects are less acceptable than for other classes of drugs used in a patient population.
In order to fully appreciate the current and proposed guidelines and the bases for the toxicity studies which have been carried out on oral contraceptives, it might be useful to review the evolution of the Food and Drug Administration guidelines for drugs including the contraceptive steroids.
EVOLUTION OF DRUG REGULATORY GUIDELINES By way of background, the Food and Drug Cosmetic (FDC) Act of 1906 was established in order to protect the American consumer from the sale of contaminated food and medicine of inferior quality (1 5). However, the act was not sufficiently broad in scope to ensure efficacy and safety. Following the death of more than 100 individuals from liver failure as a result of being given an antibiotic which contained propylene glycol as a solvent, the United .
States Congress gave further impetus to the regulation with the passage of the Food and Drug Cosmetic Act Of 1938 (4)-In addition to creating the Food and Drug Administration (FDA), this act TOXICOLOGIC PATHOLOGY ufacturer to determine the type of tests to be done and the interpretation of the results. The decision to initiate clinical trials was left entirely to the discretion of the sponsor. It was only at the application for a marketing license that sponsors of new drugs were required to submit safety data to the FDA to support claims that safety had been investigated and established (1, 23) .
The oral contraceptives were first introduced in the early 1960s (1 2) during the time when regulatory guidelines were only beginning for other classes of drugs. There were no explicit requirements for the toxicological evaluation of the oral contraceptive steroids. At that time, only the notion existed that the requirements for oral contraceptives should be more stringent than for other classes of drugs. Public concern about safety of drugs climaxed with the thalidomide disaster of 1961 in which pregnant women, who took the drug to alleviate morning sickness in early pregnancy, delivered offspring with serious reduction defects, primarily of the arms and legs (1, 19) . It was in the wake of this disaster that the last 'major revision of the 1938 Food and Drug Cosmetic Act occurred in 1962 with the passage of . the Kefauver-Harris Amendment (9). This amendment mandated for the first time the submission of animal safety data to the FDA prior to the use of any new drug in humans. It also reinforced efforts to protect the consumer against another thalidomide tragedy by preventing unnecessary exposure of humans to useless drugs and increased the information available to make riskmenefit assessments. Following passage of the Kefauver-Harris Amendment, detailed requirements for safety testing of new drugs and the Investigation New Drug Regulations were implemented (1). New guidelines for toxicity tests for drugs were drawn up based on the intended clinical use "of the drug, the duration . of treatment, and the intended route of administra-' tion (8). Clinical studies were defined in the 3 phases (Phases I, 11, and 111), each' phase being preceded by specific animal toxicity studies. At this time, the OCs were being tested in accordance with the FDA's requirements for orally administered drugs intended for unlimited periods of use. The first proposed Guidelines for Oral Contraceptives were presented to the FDA Advisory Committee for Obstetrics and Gynecology in November 1965 (1). These guidelines required toxicity studies for a maximum duration of 2 yr in rats, dogs, and monkeys. They were just being implemented in 1966 when, as a result of toxicity studies of a progestin MK 665 (1, 15, 19) (a chloro-ethyl derivative of norethindrone), an increased incidence of mammary tumors in female beagle dogs was noted in 2-yr studies. This finding led to the withdrawal of certain progestins from the market and termination of clinical trials and blocked the further development of similar compounds (2). This led to the FDA' s requirement for 7-yr studies in dogs and 10-yr studies in monkeys (12). In retrospect, some of the decisions made subsequent to the mammary findings in dogs may have been inappropriate based on our knowledge of oral contraceptives today. A number of countries have chosen to discontinue the requirement of the 7-yr dog study based on the differences between the beagle and the human female in their sensitivity to and metabolism of progestins (14, 23, 24) . Such countries include the United Kingdom, Australia, and Germany. Experience with these studies suggests that most of the changes seen in animals represent exaggerated pharmacologic responses to excessive doses of estrogens and progestins. These responses are manifested by increased endocrine tumors, liver cell hyperplasia in rats, obesity, mammary tumors, Cushingoid syndrome, abnormal carbohydrate metabolism, aTromegaly, cystic endometrial hyperplasia, pyometra and leiomyomas in dogs, changes in liver function, suppression of menstruation and leiomyomas in monkeys (2, 14) .
CURRENT GUIDELINES FOR SAFETY EVALUATION
OF STEROIDAL CONTRACEPTIVES The preclinical toxicity studies which are required to support Phase I clinical trials include acute toxicity studies in at least 2 rodent and 1 non-rodent species and by at least 2 routes of administration. Since the contraceptive steroids are administered for prolonged periods, multidose studies given at a minimum of 3 dose levels and for 90 days duration must also be conducted in rats, dogs, and monkeys (Table I ).
If the toxicity results are favorable, then the first clinical trial (Phase I) can be started. Phase I clinic'al study is a human safety study usually of short duration and directed at studying dose tolerance and clinical pharmacology of the drug in approximately 10-20 subjects.
If the Phase I trial is successful, the Phase I1 investigation will be conducted in approximately 50-100 subjects for at least 4 menstrual cycles and under rigidly controlled protocols. The purpose of Phase I1 is to demonstrate optimal dosage, efficacy, and relative safety. However, before Phase I1 studies can . be started, a great deal more animal toxicity studies must be completed. This includes 12-month studies in rats, dogs, and monkeys and teratology study in rats and rabbits. It may also be necessary to demonstrate a return to fertility following the anti-fertility effects of the drug.' Phase I11 clinical trials, which subsequently ensue, are conducted in up to 1,000 subjects and under field conditions. The main objective is to gather additional evidence of efficacy and safety. Before starting Phase I11 clinical trials, a sponsor must complete 2-yr studies in rats, dogs, and monkeys and initiate 7-and 10-yr toxicity studies in dogs and monkeys. These latter studies need not be completed before Phase 111, but must be ongoing and the sponsor must submit quarterly progress reports covering clinical and clinicopathologic findings and pathology data on animals which die. Prior to or during Phase I11 clinical studies general fertility and reproductive performance and perinatal and postnatal effects must be assessed in animals. There are no additional toxicity studies required for the NDA unless there are some unexplained observations in the routine studies which may require further investigation such as determination of mechanism. Once the drug is marketed, the epidemiologist will take over, and over the ensuing years there will be a continuous monitoring of the areas of concern, neoplasia, metabolic effects, etc.
L

DESIGN OF LONG-TERM STUDIES
IN DOGS, MONKEYS AND RATS
The procedures for safety evaluation of new drugs have been reviewed in great detail in several publications (4,ll). There are individual reviews which describe the methods for the conduct of various types of toxicity studies (20-22).
The methods utilized in the conduct ofacute, subchronic, chronic, carcinogenicity and reproductive studies of oral contraceptives are similar to $her categories of drugs. However, since the 7-and 10yr studies in dogs and monkeys, respectively, are unique requirements for OCs it may be appropriate to briefly review some of the essential elements of the study designs. These include: Animal Models, Duration, Dosage Consideration, Route of Administration, and Parameters Evaluated. These are summarized in Table 11 .
AiiirnaI Models
In practice, oral contraceptives are tested in widely differing mammalian species in anticipation that one species will react like the human. The recommended species for the testing of oral contraceptive steroids are the rat, dog, and monkey. The relevance ofthese species has been challenged from time to time and we know that certain findings do not extrapolate to women. Evaluation of the results of animal safety studies must be interpreted with some caution especially due to species differences in response of target tissue to very high pharmacologic doses of steroids administered for prolonged periods of time. Experience has shown that effects of hormones differ from one animal species to another (6). This is partially explained on the basis that similar reproduc-, tive functions are often controlled by different sex hormones and interactions. The imporiant hormones in regulating the functions of the reproduc- .
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McIENZIE TOXICOLOGIC PATHOLOGY tive system are secreted in different amounts, and target organ sensitivity varies considerably in various species (27) . Knowledge of species specific differences is critical to the design and interpretation of results. These differences can greatly affect the results of toxicity studies. It is not the purpose of this paper to go into a lengthy discussion of the pros and cons of each species; however, I will make a few comments about each. The papers to follow will discuss the unique features of each species more fully.
Rat. The rat has a very short estrus cycle of 4-5 days compared to the 30-day cycle in humans. This results in an overlap of the follicular and luteal phases so that more progesterone than normal is secreted from unovulated follicles. Prior to ovulation there is an LH surge which causes follicular rupture and simultaneous peaks. The ratio of estrogen to progestin used in these studies is unphysiological in rodents in that the strongly estrogenic component dominates.
Activation ofcertain regulatory centers, which are either absent or not present to the same extent in women, explains the occurrence of some toxicologic findings in rats. Ovarian steroids influence the secretion of pituitary hormones qualitatively and quantitatively. Estrogens cause marked release of prolactin in rats. Prolactin is mammatrophic in the murine species and therefore explains the occurrence of mammary tumors in susceptible strains of rats (6, 16, 23, 25) .
Dog. It appears that many important differences exist between the beagle dog and the human which challenge the relevance of many findings in the dog (13). The dog has an estrus cycle of 6 to 9 months compared to 30 days in the rhesus monkey and in humans. For example, the pharmacokinetic pattern of estradiol differs from the human. The dog is p imanly a fecal excreter and the human is urinary (14). Long-term administration of progesterone in dogs stimulates secretion of growth hormone (STH) which explains the increased incidence of mammary tumors (5, lo), acromegaly (3), and diabetic syndrome (17). The role of STH in the induction of mammary neoplasia in the canine species is further substantiated by the fact that high doses of potent progestin such as cyproterone acetate (40 mg/kg) does not cause any meaningful stimulation of mammary growth in hypophysectomized female dogs (7). In the human, on the other hand, STH seems to play a minor role, whereas prolactin has an important role in mammogenesis and lactogenesis (5). The dog is also very sensitive to estrogen. Moderate amounts of estradiol produce myeloid aplasia, anemia, and hemorrhage (14). Whereas estrogen is required for mammary growth in most species, pro-gesterone alone promotes mammary growth in the dog (16).
Rhesirs Monkey. The monkey has been used extensively presumably b'ecause it is phylogenetically closer to man than other experimental species and there is the presumption that findings in the primate are therefore more relevant to humans. Most of the basic reproductive processes are more similar to man than that of the dog or rodent. This is especially true of the endocrine mechanisms controlling the menstrual cycle and the relative lengths of the control mechanisms ofgestation. Some differences have been described with respect to implantation, cervical anatomy, and metabolism of progestational compounds (1 3).
Dtiratioii
Traditionally, 2 yrs has been accepted as the upper limit of the life span of a rat and therefore, carcinogenicity studies are of 2 yr duration. The avgrage mortality at 2 yr is approximately 50% (18). The treatment period of 7 and 10 yrs in dogs and monkeys, respectively, was determined to represent approximately half of the life span of both species and would allow for expression of the spontaneous tumor ofthe species. The tendency to express exposure as a fraction of life span is based on the assumption that age changes play a part in the development of toxicity. The alternative is to assume that certain toxicity signs require a certain period of time before they will appear at a particular dose level (18).
Dosage Considerations
In general, exposure is achieved by once per day dosing for 7 days per week. Rats are dosed daily throughout the entire course of the 2 yr of the carcinogenicity study. Dogs and monkeys are dosed for 3 weeks each month and 1 week ofdrug withdrawal. This is to simulate the clinical regimen. The choice ofdose should allow for determination of toxic responses that can be employed in risk benefit assessment. The low dose is usually set at 2-5 times the anticipated clinical dose on a milligram per kilogram of body weight and is intended to give an indication of a non-toxic dose level. The intermediate dose represents a geometric mean between the low and the high dose. The high dose is aimed at identifying toxic effects and may represent the. maximum tolerated dose. The high-dose level should be carefully selected so as not to jeopardize survival of the animals. The current requirements for doses are that the drug be administered at 1, 10, and 25 times the anticipated clinical dose in dogs and 1, 10, and 50 times the anticipated clinical dose in monkeys (1 1,25) . The reduced multiple of the high- dose in the dog is made on the basis of the extreme sensitivity of the dog to the female sex steroids (14). In the rat, the high dose usually ranges from 200-400 and occasionally up to 1,000 times the anticipated clinical dose. These multiples have created a dramatic hormonal imbalance in favor of the estrogenic component.
With the steroids, one usually sees exaggerated pharmacologic responses rather than frank toxicity. The metabolic and kinetic features ofthe drug should be the dose limiting determinants. It is clearly inappropriate to increase the dose beyond the point at which absorption from the gastrointestinal tract becomes saturated. It should then be appropriate to limit the high dose to a realistic multiple of the clinical dose.
Route of Adiiiinistration
The route of administration for toxicity studies in general is the intended clinical route, which is oral. Since the distributiqn of the drug and its me-tabolite@) and the consequent exposure to the various tissues will 'vary with the route of administration, any extrapolation from animal to human can be made with a greater degree of confidence if the routes are the same. 
Paraineters Evaluated
Tables 111-VII show the various parameters which are evaluated in the 7-and 10-yr studies in dogs and monkeys, respectively.
PROPOSED GUIDELINES FOR
NEW STEROID CONTRACEPTIVES
Since the introduction of the steroidal contraceptives nearly 3 decades ago, their safety has been frequently challenged; however, efficacy has not been seriously questioned. Much emphasis has been devoted to reconciling the toxicological findings in animals with clinical epidemiological experience in women taking steroidal contraceptives (27) .
Although it is generally felt that the requirements for the development of OCs should be more stringent than for other drug classes because of their widespread use in healthy women, the animal studies, including the 7-yr dog and 10-yr monkey studies which were designed specifically for this purpose, have been extensively challenged as to their contribution to a better understanding of the toxicity POtential and their clinical relevance.
As new data became available from the long-term studies, it is now clear that there are differences in reproductive physiology (and hence responsiveness of target organs to different steroidal drugs) between man and the recommended animal models (2, 14, 26) . Furthermore, epidemiological studies have shown that owing to these differences it is not possible to completely predict all the effects of contra-ceptive steroids in humans on the basis of animal studies (24). Based on these observations, the need for updating and refining of the requirements for safety testing of steroidal contraceptives became more obvious. The World Health Organization through its Special Program Committee has been for many years a major proponent for reviewing and revising the present preclinical requirements for the evaluation of steroid contraceptives. At the International Conference on Population held in Mexico City in August 1984, a resolution was passed to update the official requirements for the preclinical and clinical assessment of new fertility regulating agents (24). In response to this recommendation, the Special Program of Research and Development and Research Training in Human Reproduction of WHO convened in Geneva, Switzerland from February 2-5, 1987 to discuss methods for Improving the Safety Requirements for Contraceptive Steroids (24). The symposium was attended by basic and clinical scientists, representatives of the'industry, and consumer groups. The proceedings of the meeting discussed the current approaches to the evaluation of safety of contraceptive steroids and their inherent strengths and weaknesses as a basis for their recomme'ndations (24). Recommendations were made which should increase the relevance and reliability of preclinical and clinical data for the assessment of efficacy and safety of contraceptive steroids. The recommendations were submitted to National Regulatory Authorities for their consideration. In August 1987, the FDA's Advisory Committee on Fertility and Maternal Health met to review and discuss the WHO recommendations on "Guidelines for Toxicological and Clinical Assessment and Post-Registration Surveillance of Steroidal Contraceptive Drugs." The FDA indicated areas in which they will consider some modifications of the existing guidelines ( Table VIII) . The FDA proposes acute toxicity studies in 3-4 species and multidose toxicity studies of at least 2 weeks duration in a rodent and non-rodent (preferably monkey) with at least 3 dose levels in support of Phase I clinical trials. In the acute studies, the determination of an approximate lethal dose is adequate. There is no scientific need for conducting studies to determine a precise LD50 value. Phase I1 trials would be started following the completion of multidose toxicity studies of at least 4 weeks duration in a rodent and non-rodent species. Reproductive performance and fertility, teratogenicity as well as pennatal, postnatal studies, including examination of fertility in the F, generation must be conducted. A return to fertility following cessation of treatment and possible effects of treatment on progeny should be included in the reproductive studies; Multidose toxicity studies of at least 6 months duration in rodent and non-rodents and ini- Interm reports of 7-and 10-yr studies at SAGE PUBLICATIONS on December 9, 2012 tpx.sagepub.com Downloaded from tiation of long-term carcinogenicity studies in rats (24 months) and mice (18 months) are required for Phase 111.
For NDA approval there is a requirement for completion of 1 yr toxicity studies in rodent and non-rodent species. In addition, there is a 3-yr dog study as an interim requirement until 1989 when an ongoing epidemiological study in Depo-Provera is completed.
It is hoped that these new approaches will provide investigators with a more meaningful basis for assessment of human risk than that obtained with the current methods.
